ASP Isotopes (NASDAQ:ASPI) Trading 5.6% Higher - Still a Buy?

Key Points

• ASP Isotopes Inc. shares increased by 5.6% to $9.47, despite a significant 74% decline in trading volume compared to the average.
• Analysts have mixed ratings on ASPI, with a "buy" rating from Canaccord Genuity and a "sell" rating from Weiss Ratings, leading to an average rating of "Hold" and a target price of $11.00.
• ASP Isotopes reported a negative EPS of ($1.03), significantly missing expectations and indicating a negative net margin of 2,181.62% for the quarter.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report)'s share price traded up 5.6% during trading on Tuesday . The company traded as high as $9.48 and last traded at $9.47. 892,160 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 3,450,342 shares. The stock had previously closed at $8.97.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ASPI shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of ASP Isotopes in a research report on Saturday, September 27th. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 price objective on shares of ASP Isotopes in a research report on Wednesday, September 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $11.00.

ASP Isotopes Price Performance

The company has a current ratio of 14.72, a quick ratio of 14.56 and a debt-to-equity ratio of 3.53. The firm has a market cap of $817.63 million, a P/E ratio of -14.57 and a beta of 3.29. The firm has a 50-day simple moving average of $9.51 and a 200-day simple moving average of $7.81.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%. The business had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.60 million. As a group, analysts forecast that ASP Isotopes Inc. will post -0.24 EPS for the current year.

Insider Buying and Selling

In related news, Director Duncan Moore sold 75,000 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $9.28, for a total transaction of $696,000.00. Following the completion of the transaction, the director directly owned 994,553 shares of the company's stock, valued at $9,229,451.84. This represents a 7.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Robert Ainscow sold 8,438 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $8.53, for a total transaction of $71,976.14. Following the completion of the transaction, the chief operating officer directly owned 1,411,554 shares of the company's stock, valued at approximately $12,040,555.62. This trade represents a 0.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 383,699 shares of company stock valued at $3,412,977 over the last ninety days. Company insiders own 21.40% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ASPI. Rovida Advisors Inc. acquired a new stake in ASP Isotopes during the second quarter worth approximately $16,148,000. Rovida Investment Management Ltd boosted its position in ASP Isotopes by 528.6% during the second quarter. Rovida Investment Management Ltd now owns 2,200,000 shares of the company's stock worth $16,148,000 after acquiring an additional 1,850,000 shares during the last quarter. Exchange Traded Concepts LLC acquired a new stake in ASP Isotopes during the second quarter worth approximately $9,593,000. Invesco Ltd. boosted its position in ASP Isotopes by 2,205.0% during the second quarter. Invesco Ltd. now owns 471,219 shares of the company's stock worth $3,468,000 after acquiring an additional 450,776 shares during the last quarter. Finally, Philadelphia Financial Management of San Francisco LLC boosted its position in ASP Isotopes by 11.2% during the first quarter. Philadelphia Financial Management of San Francisco LLC now owns 3,508,062 shares of the company's stock worth $16,453,000 after acquiring an additional 354,517 shares during the last quarter. 16.80% of the stock is owned by hedge funds and other institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.